Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic ...
pharmaphorum9d
FDA clears first treatment for Prader-Willi syndrome
Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic ...
Endocrinology Advisor4d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
PharmExec9d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
Technology Networks9d
FDA Approves First Therapy To Treat Hyperphagia in Prader-Willi Syndrome
Soleno Therapeutics today announced that the US FDA has approved VYKAT XR (diazoxide choline) extended-release tablets, for ...
Monthly Prescribing Reference9d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
Study participants with hyperphagia and PWS were randomly assigned to receive diazoxide choline extended-release (n=38) or placebo (n=39). The primary endpoint was the change from baseline to week ...